PharmaBoardroom

Nine months ago you were appointed CEO of the company. What brought you to Dx assays? I think Dx Assays is a very interesting opportunity, which is…

Before we get into the company’s activities and market, could you give us a brief rundown of your past working experience prior to Alandra…

Would you begin by outlining the key milestones & achievements of the NHMRC in the past four years? The first point is the development of our…

Lilly has invested over one billion EUR in its Kinsale site to date—including a recent 330 million EUR expansion that positions Ireland as a key…

Could you tell our readers who are not familiar with the Biopark with an introduction of the Biopark and its institutes? The BioPark of Charleroi…

The generics market in Belgium doesn’t seem to be at the level it deserves to be. Considering that Mylan controls about 14% of the local…

Dr. Rumler, what is your assessment of the subsidiary’s current strengths and weaknesses, after three and half years of tenure? Pfizer…

Austria has always been a strategic market for the group: it has played a key role in Boehringer Ingelheim’s success story, as this is where the…

Dr Spatz, what would you highlight as the main specificities of the Austrian generic market, and explain how Teva has adapted its approach to the…

Business & Decision Life Science was founded back in 2007, although that department existed within the group’s structure long before that.…

Mr Hendrickx, considering that you have been with Sanofi for over a decade, what would you describe as the single most important change in…

Dr. Nikitsch, you started Menarini’s Austrian operations almost 13 years ago. Would you say that Menarini’s presence in Austria today…